FilingSEC EDGAR8-K
Processa Pharmaceuticals Updates on VT-7208 Clinical Progress and Shareholder Proposals
· SEC accepted
StagePhase 2
Filing content
Processa issued a shareholder letter detailing progress on its VT-7208 Phase 2 clinical program and upcoming shareholder votes regarding a reverse stock split and preferred stock conversion.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…